A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Summary

This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
• Hematopoietic and Lymphatic System Neoplasm
• Hodgkin Lymphoma
• Lymphoblastic Lymphoma
• Myelodysplastic Syndrome
• Myelofibrosis
• Myeloproliferative Neoplasm
• Non-Hodgkin Lymphoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 75 years

Sex

All

Healthy volunteers

Accepted

Sponsor

City of Hope Medical Center

Last updated on ClinicalTrials.gov

July 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites